Nicole B Jacobson,Neha Parekh,Matt Kalaycio
Nicole B Jacobson
Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition i...
Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy [0.03%]
伊马替尼联合化疗治疗费城染色体阳性急性淋巴细胞白血病
Ryuzo Ohno;Japan Adult Leukemia Study Group
Ryuzo Ohno;Japan Adult Leukemia Study Group
The presence of the Philadelphia chromosome (Ph) is associated with a very poor prognosis in acute lymphoblastic leukemia (ALL). Although hematologic complete remission (CR) is achieved in 50% to 80% of adult patients by intensive chemother...
Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults [0.03%]
成人新诊断急性淋巴细胞白血病的临床表现与治疗
Heather Landau,Nicole Lamanna
Heather Landau
Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups. The treatment of adults with ALL has evolved largely from the therapy developed for childhood ALL and, despite differences ...
The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era [0.03%]
酪氨酸激酶抑制剂时代异基因干细胞移植在慢性髓性白血病治疗中的作用
Corey Cutler,Joseph H Antin
Corey Cutler
Allogeneic stem cell transplantation is an accepted standard therapy for chronic myeloid leukemia (CML). In recent years, however, the use of transplantation has diminished, largely because of the introduction of the novel tyrosine kinase i...
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction [0.03%]
聚合酶链反应在慢性粒细胞白血病BCR-ABL检测中的应用监测治疗效果
Vivian G Oehler,Jerald P Radich
Vivian G Oehler
The sensitive detection of minimal residual disease by the polymerase chain reaction (PCR) has revolutionized our ability to follow treatment response and predict relapse. Examples of how the detection of minimal residual disease can drive ...
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate [0.03%]
伊马替尼治疗慢性髓性白血病疗效的进一步观察
Jeffrey A Zonder,Charles A Schiffer
Jeffrey A Zonder
Imatinib (imatinib mesylate, Gleevec(R) [formerly known as STI571], Novartis Pharmaceuticals, Basel, Switzerland) is a protein tyrosine kinase inhibitor that is approved by the US Food and Drug Administration for patients with all phases of...
Javeed Iqbal,Francesco d&#x;Amore,Qinglong Hu et al.
Javeed Iqbal et al.
Molecular diagnostics for lymphoid malignancies has undergone substantial technical evolution during the past two decades, moving from labor-intensive investigations of individual abnormalities to high-throughput genome-wide analyses. Accor...
Is cytarabine required in the treatment of acute promyelocytic leukemia? [0.03%]
治疗急性早幼粒细胞白血病需要使用阿糖胞苷吗？
Lionel Adès,Pierre Fenaux
Lionel Adès
Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia. Many studies have shown that treatment with a...
Clinical implications of gene expression profiling of acute myeloid leukemia [0.03%]
急性髓系白血病基因表达谱的临床意义
Kenneth I Mills,Amanda F Gilkes
Kenneth I Mills
Since the first demonstration in 1999 that gene expression profiling could distinguish between different variants of acute leukemia, several studies have analyzed patients with acute myeloid leukemia on the basis of cytogenetics, morphologi...
Kenneth Bradstock
Kenneth Bradstock
Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and furt...